522‑054
Dual allosteric cognitive enhancer: α7 nicotinic PAM and α5 GABA-A inhibitor, preclinical data only.
Pharmacology
Contents
WHAT IS 522-054?
Detailed overview
522-054 is an experimental triazolopyridazine cognitive enhancer that modulates two related ligand-gated ion channels at once: it positively potentiates α7 nicotinic acetylcholine receptors while inhibiting α5-subunit-containing GABA-A receptors. This dual action simultaneously strengthens excitatory cholinergic signaling and reduces inhibitory GABAergic tone in the hippocampus, which in animal models produces unusually low effective doses and lowers the threshold for long-term potentiation (LTP). In rodents it improved learning and memory, reversed scopolamine-induced attention and memory deficits, and enhanced cognitive recovery in a chronic traumatic brain injury model. There are no human clinical trials: the compound has never been tested in humans, so it exists only as an experimental research chemical.
Mechanism
α7 nicotinic PAM + α5 GABA-A inhibitor
Evidence
Preclinical only (no human data)
Legal status
Unapproved research chemical
Receptor profile
- α7 nicotinic acetylcholine receptor (positive modulator)Strong
- α5-subunit GABA-A receptor (negative modulator)Strong
- Long-term potentiation (LTP) in the hippocampusModerate
Safety
Side effects, stop signs, contraindications
Side effects · 5
- No human safety data: only preclinical (rodent) studies exist; the compound has never been tested in humans
- The long-term effects of combined α7 nicotinic and α5 GABA-A modulation in humans are unknown
- Reducing inhibitory GABAergic tone may theoretically increase seizure susceptibility or anxiety
- Because of the bell-shaped (inverted-U) dose-response seen in animals, a higher dose is not necessarily more effective
- Unknown pharmacokinetics and toxicity profile in humans
Contraindications · 4
- Pregnancy and breastfeeding: safety not established, avoid
- Epilepsy or lowered seizure threshold: α5 GABA-A inhibition may theoretically increase seizure risk
- Not an approved medicine; experimental research chemical, not recommended without clinical supervision
- Unknown interactions with other cholinergic or GABAergic agents
Related Nootropics
Same therapeutic category
Studies
Related research and clinical findings
Nootropic alpha7 nicotinic receptor allosteric modulator derived from GABAA receptor modulators
Ng HJ, Whittemore ER, Tran MB, Hogenkamp DJ, Broide RS, Johnstone TB, Zheng L, Stevens KE, Gee KW
Allosteric modulation of related ligand-gated ion channels synergistically induces long-term potentiation in the hippocampus and enhances cognition
Timmermann DB, Sandager-Nielsen K, Dyhring T, Ahring PK, Jensen ML, Nielsen EO, et al.
Enhancing cognitive recovery in chronic traumatic brain injury through simultaneous allosteric modulation of α7 nicotinic acetylcholine and α5 GABA(A) receptors
et al.
FAQ
FAQ
Dual allosteric cognitive enhancer: α7 nicotinic PAM and α5 GABA-A inhibitor, preclinical data only.
Telegram
Have a question about 522‑054?
Reach out to us on Telegram for a personalized stack. We'll be happy to help.
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
Structure & chemistry
The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.